×
Arvinas Net Current Debt 2017-2025 | ARVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Arvinas net current debt from 2017 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Arvinas Net Current Debt 2017-2025 | ARVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Arvinas net current debt from 2017 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$214.8B
Amgen (AMGN)
$160.4B
Gilead Sciences (GILD)
$135.3B
Vertex Pharmaceuticals (VRTX)
$119B
Bristol Myers Squibb (BMY)
$97.8B
CSL (CSLLY)
$78.3B
GSK (GSK)
$74.7B
Regeneron Pharmaceuticals (REGN)
$59.4B
Alnylam Pharmaceuticals (ALNY)
$42.3B
Argenex SE (ARGX)
$35B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$19.9B
Insmed (INSM)
$19.8B
Biogen (BIIB)
$18.9B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$14.5B
Genmab (GMAB)
$14.1B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$12.5B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.2B
Ascendis Pharma (ASND)
$10.8B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.9B
Legend Biotech (LEGN)
$7.7B